Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study
Clinical Pharmacology & Therapeutics · 2026-06 · 119 (6) · 1628-1637
DOI: 10.1002/cpt.70258 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 14.03.2026. Verfasst von Teng-Li Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Psoriasis, Dermatitis, Atopic, Alopecia Areata. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
Janus kinase inhibitors (JAKis) have emerged as effective treatments for several skin immune‐mediated inflammatory diseases (IMIDs). However, safety concerns have been raised due to boxed warnings from rheumatoid arthritis trials, and whether these risks apply to skin IMIDs remains uncertain. This multinational retrospective cohort study used the TriNetX database to compare the real‐world safety of JAKis and conventional immunomodulators (cIMs) in patients aged 12 years or older with skin IMIDs (psoriatic disease, atopic dermatitis, or alopecia areata). Patients newly prescribed JAKis (tofacitinib, upadacitinib, deucravacitinib, baricitinib, abrocitinib, or ritlecitinib) were propensity score–matched (1:1) with those prescribed cIMs (methotrexate or cyclosporine) based on demographics, baseline skin IMIDs, and comorbidities, yielding 17,068 matched patients. Over 2 years, the JAKi cohort showed lower incidences of all‐cause mortality (0.28% vs. 0.62%; P = 0.015) and major adverse cardiovascular events (MACE; 1.15% vs. 1.95%; P = 0.005) than the cIM cohort, corresponding to reduced risks (mortality: HR, 0.47; 95% CI, 0.25–0.88; MACE: HR, 0.63; 95% CI, 0.46–0.88). Risks of venous thromboembolism (HR, 0.80; 95% CI, 0.43–1.48) and malignancy (HR, 0.85; 95% CI, 0.63–1.16) were not increased. Subgroup analyses, including older adults and those with cardiometabolic risk factors, showed no signal of increased risk, with consistent findings across available agent‐level and sensitivity analyses. These results suggest that, over 2 years, JAKis are not associated with increased risks of mortality, MACE, venous thromboembolism, or malignancy compared with conventional systemic agents in patients with skin IMIDs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
- Program of Interdisciplinary Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
- Department of Internal Medicine, Division of Chest Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan.
- Department of Dermatology, Taichung Veterans General Hospital, Taichung, Taiwan.
- Graduate Institute of Clinical Medicine, National Chung Hsing University, Taichung, Taiwan.
ORCID-Profile: Teng-Li Lin, Yi-Ju Chen, Chun-Ying Wu
Zitieren
APA
Lin, T. L., Fan, Y. H., Fan, K. S., Juan, C. K., Chen, Y. J., & Wu, C. Y. (2026). Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study. Clinical Pharmacology & Therapeutics, 119(6), 1628-1637. https://doi.org/10.1002/cpt.70258
Vancouver
Lin TL, Fan YH, Fan KS, Juan CK, Chen YJ, Wu CY. Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study. Clinical Pharmacology & Therapeutics. 2026;119(6):1628-1637. doi:10.1002/cpt.70258
BibTeX
@article{Lin2026,
author = {Lin, Teng-Li and Fan, Yi-Hsuan and Fan, Kuo-Sheng and Juan, Chao-Kuei and Chen, Yi-Ju and Wu, Chun-Ying},
title = {Real‐World Safety of JAK Inhibitors in Skin Immune‐Mediated Inflammatory Diseases: Boxed Warning Outcomes from a Multinational Cohort Study},
journal = {Clinical Pharmacology & Therapeutics},
year = {2026},
volume = {119},
number = {6},
pages = {1628--1637},
doi = {10.1002/cpt.70258}
}
EUVIMED